- A031501 AMBASSADOR (Urothelial)
A Phase III Randomized Adjuvant Study of MK-3475 (PEMBROLIZUMAB) in Muscle Invasive and Locally Advanced Urothelial Carcinoma versus Observation
- A031902 CASPAR (Prostate)
A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First line Metastatic Castration-Resistant Prostate Cancer
- A081105 ALCHEMIST - SUBSTUDY (Lung)
Randomized Study of Erlotinib VS Observation In Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
- A171901 (Lung)
Older Non-Small Cell Lung Cancer Patients (= 70 Years of Age) Treated with Firstline MK-3475 (Pembrolizumab) +/- Chemotherapy (Oncologist's/Patient's Choice)
- EA5142 ALCHEMIST - SUBSTUDY (Lung)
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL): A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
- EA8143 PROSPER RCC (Renal)
A Phase III Randomized Study Comparing Perioperative NIVOLUMAB vs. OBSERVATION in Patients with Renal Cell Carcinoma Undergoing Nephrectomy
- S1207 (Breast)
A Phase III Randomized, Placebo- Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor Positive and HER2/NEU Negative Breast Cancer
- S1320 (Melanoma)
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093 in BRAFV600E/K Mutant Melanoma
- S1400F LUNGMAP - SUBSTUDY (Lung)
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (LungMAP Non-Match Substudy)
- S1418-BR006 (Breast)
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor Negative Breast Cancer with = 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+)After Neoadjuvant Chemotherapy
